Financhill
Buy
54

NVS Quote, Financials, Valuation and Earnings

Last price:
$109.06
Seasonality move :
5.08%
Day range:
$107.64 - $109.30
52-week range:
$92.35 - $120.92
Dividend yield:
3.55%
P/E ratio:
18.55x
P/S ratio:
4.29x
P/B ratio:
4.89x
Volume:
1.3M
Avg. volume:
2.2M
1-year change:
11.14%
Market cap:
$215.4B
Revenue:
$51.7B
EPS (TTM):
$5.88

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NVS
Novartis AG
$13.6B $2.24 6.82% 57% $108.96
ABBV
AbbVie
$14.7B $3.09 5.05% 227.63% $211.73
GSK
GSK PLC
$10.1B $1.05 2.57% 57.14% $43.42
LLY
Eli Lilly and
$14.2B $5.47 45.75% 89.16% $1,006.63
PFE
Pfizer
$13.5B $0.57 -3.03% 29.69% $31.32
RHHBY
Roche Holding AG
$17.9B -- -- -- $46.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NVS
Novartis AG
$109.06 $108.96 $215.4B 18.55x $3.87 3.55% 4.29x
ABBV
AbbVie
$211.77 $211.73 $373.8B 88.24x $1.64 2.97% 6.67x
GSK
GSK PLC
$39.49 $43.42 $80.5B 24.94x $0.40 3.94% 2.04x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
PFE
Pfizer
$25.72 $31.32 $145.8B 18.24x $0.43 6.57% 2.30x
RHHBY
Roche Holding AG
$43.26 $46.29 $275.3B 30.14x $1.35 3.12% 3.96x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NVS
Novartis AG
40.07% 0.604 15.32% 0.80x
ABBV
AbbVie
95.28% -0.007 22.34% 0.43x
GSK
GSK PLC
53.74% 0.176 29.19% 0.49x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
RHHBY
Roche Holding AG
52.17% 0.691 16.91% 1.19x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NVS
Novartis AG
$10.2B $3.5B 16.91% 27.64% 26.26% $3.1B
ABBV
AbbVie
$10.7B $84M 5.68% 61.64% -10.38% $6.8B
GSK
GSK PLC
$7.1B $2.8B 8.51% 19.22% 8.71% $1.5B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
RHHBY
Roche Holding AG
-- -- 12.15% 23.8% -- --

Novartis AG vs. Competitors

  • Which has Higher Returns NVS or ABBV?

    AbbVie has a net margin of 20.79% compared to Novartis AG's net margin of -0.15%. Novartis AG's return on equity of 27.64% beat AbbVie's return on equity of 61.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
    ABBV
    AbbVie
    70.89% -$0.02 $70.5B
  • What do Analysts Say About NVS or ABBV?

    Novartis AG has a consensus price target of $108.96, signalling downside risk potential of -0.09%. On the other hand AbbVie has an analysts' consensus of $211.73 which suggests that it could fall by -0.02%. Given that Novartis AG has more downside risk than AbbVie, analysts believe AbbVie is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 9 2
    ABBV
    AbbVie
    11 10 0
  • Is NVS or ABBV More Risky?

    Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison AbbVie has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.616%.

  • Which is a Better Dividend Stock NVS or ABBV?

    Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.55%. AbbVie offers a yield of 2.97% to investors and pays a quarterly dividend of $1.64 per share. Novartis AG pays 63.85% of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but AbbVie's is not.

  • Which has Better Financial Ratios NVS or ABBV?

    Novartis AG quarterly revenues are $13.6B, which are smaller than AbbVie quarterly revenues of $15.1B. Novartis AG's net income of $2.8B is higher than AbbVie's net income of -$22M. Notably, Novartis AG's price-to-earnings ratio is 18.55x while AbbVie's PE ratio is 88.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.29x versus 6.67x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
    ABBV
    AbbVie
    6.67x 88.24x $15.1B -$22M
  • Which has Higher Returns NVS or GSK?

    GSK PLC has a net margin of 20.79% compared to Novartis AG's net margin of 5.1%. Novartis AG's return on equity of 27.64% beat GSK PLC's return on equity of 19.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
    GSK
    GSK PLC
    68.47% $0.26 $36.4B
  • What do Analysts Say About NVS or GSK?

    Novartis AG has a consensus price target of $108.96, signalling downside risk potential of -0.09%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 9.96%. Given that GSK PLC has higher upside potential than Novartis AG, analysts believe GSK PLC is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 9 2
    GSK
    GSK PLC
    2 3 1
  • Is NVS or GSK More Risky?

    Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.601, suggesting its less volatile than the S&P 500 by 39.914%.

  • Which is a Better Dividend Stock NVS or GSK?

    Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.55%. GSK PLC offers a yield of 3.94% to investors and pays a quarterly dividend of $0.40 per share. Novartis AG pays 63.85% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or GSK?

    Novartis AG quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $10.4B. Novartis AG's net income of $2.8B is higher than GSK PLC's net income of $530.1M. Notably, Novartis AG's price-to-earnings ratio is 18.55x while GSK PLC's PE ratio is 24.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.29x versus 2.04x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
    GSK
    GSK PLC
    2.04x 24.94x $10.4B $530.1M
  • Which has Higher Returns NVS or LLY?

    Eli Lilly and has a net margin of 20.79% compared to Novartis AG's net margin of 32.59%. Novartis AG's return on equity of 27.64% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About NVS or LLY?

    Novartis AG has a consensus price target of $108.96, signalling downside risk potential of -0.09%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Novartis AG, analysts believe Eli Lilly and is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 9 2
    LLY
    Eli Lilly and
    16 4 0
  • Is NVS or LLY More Risky?

    Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock NVS or LLY?

    Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.55%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Novartis AG pays 63.85% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or LLY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Eli Lilly and quarterly revenues of $13.5B. Novartis AG's net income of $2.8B is lower than Eli Lilly and's net income of $4.4B. Notably, Novartis AG's price-to-earnings ratio is 18.55x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.29x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns NVS or PFE?

    Pfizer has a net margin of 20.79% compared to Novartis AG's net margin of 2.31%. Novartis AG's return on equity of 27.64% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About NVS or PFE?

    Novartis AG has a consensus price target of $108.96, signalling downside risk potential of -0.09%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Pfizer has higher upside potential than Novartis AG, analysts believe Pfizer is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 9 2
    PFE
    Pfizer
    6 13 1
  • Is NVS or PFE More Risky?

    Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock NVS or PFE?

    Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.55%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Novartis AG pays 63.85% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

  • Which has Better Financial Ratios NVS or PFE?

    Novartis AG quarterly revenues are $13.6B, which are smaller than Pfizer quarterly revenues of $17.8B. Novartis AG's net income of $2.8B is higher than Pfizer's net income of $410M. Notably, Novartis AG's price-to-earnings ratio is 18.55x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.29x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
    PFE
    Pfizer
    2.30x 18.24x $17.8B $410M
  • Which has Higher Returns NVS or RHHBY?

    Roche Holding AG has a net margin of 20.79% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 27.64% beat Roche Holding AG's return on equity of 23.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
    RHHBY
    Roche Holding AG
    -- -- $78.4B
  • What do Analysts Say About NVS or RHHBY?

    Novartis AG has a consensus price target of $108.96, signalling downside risk potential of -0.09%. On the other hand Roche Holding AG has an analysts' consensus of $46.29 which suggests that it could grow by 7%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVS
    Novartis AG
    0 9 2
    RHHBY
    Roche Holding AG
    3 4 0
  • Is NVS or RHHBY More Risky?

    Novartis AG has a beta of 0.540, which suggesting that the stock is 45.99% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.628%.

  • Which is a Better Dividend Stock NVS or RHHBY?

    Novartis AG has a quarterly dividend of $3.87 per share corresponding to a yield of 3.55%. Roche Holding AG offers a yield of 3.12% to investors and pays a quarterly dividend of $1.35 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NVS or RHHBY?

    Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.8B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.55x while Roche Holding AG's PE ratio is 30.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.29x versus 3.96x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Goldman Sachs Stock a Buy Sell or Hold?
Is Goldman Sachs Stock a Buy Sell or Hold?

When the Federal Reserve started hiking rates in 2022, banks’…

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock